SOLTFSOLTFOTC

Overview Intelligence Charts News Fundamentals Key Metrics Earnings Growth Financials Insiders

Latest News

globenewswire.com

Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals

Tokyo, Japan and Cambridge, UK, 5 March 2026 - Nxera Pharma Co. , Ltd. ("Nxera" or "the Company"; TSE 4565) today announces that Centessa Pharmaceuticals has achieved an additional early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX489, being developed by Centessa for the treatment of neuropsychiatric disorders.

globenewswire.com

Nxera Pharma Submits Marketing Authorization Application for Daridorexant in South Korea

Tokyo, Japan and Cambridge, UK, 4 March 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has submitted a marketing authorisation application (MAA) to the Ministry of Food and Drug Safety (MFDS) in South Korea for daridorexant, a dual orexin receptor antagonist, for the treatment of adult patients with insomnia. This submission follows positive data from the Phase 3 trial of daridorexant in South Korea which met both primary and secondary efficacy endpoints (Link).

seekingalpha.com

Nxera Pharma Co., Ltd. (SOLTF) Q4 2025 Earnings Call Transcript

globenewswire.com

Nxera Pharma Proposes Changes to its Board of Directors

Tokyo, Japan and Cambridge, UK, 13 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that its Board of Directors approved the change of Directors as stated below. The nomination of candidates for External Directors is based on the resolution of the Nomination Committee. The appointments are expected to be ratified officially, subject to the passing of resolutions to be made at the 36th Ordinary General Meeting of Shareholders, scheduled to be held on 25 March 2026.

globenewswire.com

Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2025

Tokyo, Japan and Cambridge, UK, 13 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the fourth quarter and 12 months ended 31 December 2025. The full report can be viewed here.

globenewswire.com

Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals

Tokyo, Japan and Cambridge, UK, 12 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today notes that Centessa Pharmaceuticals has achieved an early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX489, being developed by Centessa for the treatment of neuropsychiatric disorders. This milestone triggers a payment of US$1.8 million to Nxera pursuant to its research collaboration with Centessa. The milestone payment will be recognized as revenue in the first quarter of 2026.

globenewswire.com

Nxera Pharma Licenses GPCR-targeted Program to Newly Founded Spin-out Company

Tokyo, Japan and Cambridge, UK, 12 January 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announced that it has entered into a license agreement (the “Agreement”) with a newly established independent company (the “NewCo”), created by a leading international life sciences investment firm, to advance Nxera's G protein-coupled receptor (GPCR)-targeted program (the “Program”).

seekingalpha.com

Nxera Pharma Co., Ltd. (SOLTF) Presents at 44th Annual J.P.

globenewswire.com

Nxera Pharma to Receive US$3.6 Million in Milestone Payment Pursuant to Research Collaboration with Centessa

Tokyo, Japan and Cambridge, UK, 13 January 2026 - Nxera Pharma Co. , Ltd. ("Nxera" or "the Company"; TSE 4565) notes that Centessa Pharmaceuticals has achieved an early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX142, in development for the treatment of neurological and neurodegenerative disorders.

globenewswire.com

Santhera Licenses AGAMREE® (Vamorolone) to Nxera Pharma in Japan, South Korea, Australia and New Zealand in a Deal Valued at up to USD 205 Million Plus Royalties

Ad hoc announcement pursuant to Art. 53 LR Exclusive licensing agreement includes USD 40 million upfront comprising USD 30 million in cash and USD 10 million equity investment at CHF 14.91 per share, a 20% premium to the 30-day VWAP.

globenewswire.com

Nxera Pharma to Regain Full Rights to GPR52 Agonist Program for Schizophrenia

Tokyo, Japan and Cambridge, UK, 19 December 2025 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) today announces that Boehringer Ingelheim has informed the Company of its decision not to exercise its exclusive option to license Nxera's GPR52 agonist program for schizophrenia, including the Phase 2 ready lead compound NXE0048149 (“NXE'149”). No further information was provided by Boehringer Ingelheim. All rights to the GPR52 portfolio will revert in full to Nxera Pharma together with all data and intellectual property generated under the collaboration in accordance with the terms of the Collaboration and License Option Agreement.

globenewswire.com

Nxera Introduces Employee Stock Ownership Plan (J-ESOP) for Employees Residing in Japan

Tokyo, Japan and Cambridge, UK, 19 November 2025 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) announces that its Board of Directors have decided to replace the current Restricted Share Unit (“RSU”) Plan with the Employee Stock Ownership Plan (J-ESOP) (hereinafter referred to as the "Plan" and a trust established under the trust agreement to be concluded with Mizuho Trust & Banking Co., Ltd. with respect to the Plan, is referred to as the "Trust"), which grants the Company's shares to employees residing in Japan, and to establish the Share Benefit Rules (hereinafter referred to as ‘Share Benefit Rules') as set out below. This Plan provides benefits based on points upon retirement etc., thereby providing employees with tax benefits and mitigating the concentration of sales of the Company shares at specific points in time that often occur under RSU Plans.

seekingalpha.com

Nxera Pharma Co., Ltd. (SOLTF) Discusses R&D Restructuring, Pipeline Prioritization, and Focus on Obesity and Metabolism Transcript

Nxera Pharma Co., Ltd. (OTCPK:SOLTF) Discusses R&D Restructuring, Pipeline Prioritization, and Focus on Obesity and Metabolism November 18, 2025 3:00 AM EST Company Participants Hironoshin Nomura - Executive Officer & CFO Chris Cargill - Representative Executive Officer, President, CEO & Director Toshihiro Maeda - President of Nxera Pharma Japan & COO Patrik Foerch Conference Call Participants Hidemaru Yamaguchi - Citigroup Inc., Research Division Hiroshi Wada - SMBC Nikko Securities Inc., Research Division Dion Stéfan Büchner - Pathology Associates Co., Ltd.

globenewswire.com

Nxera Pharma Shares Video Interviews with Major Shareholders on Its Official YouTube Channel

Tokyo, Japan and Cambridge and London, UK, 17 November 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces the release of two video interviews with its major shareholders, available on the Company's official YouTube channel.

globenewswire.com

Nxera Announces Focused Restructuring to Enhance Path to Profitability

Tokyo, Japan and Cambridge and London, UK, 17 November 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announced a focused restructuring designed to concentrate investment and resources on efficient platforms, programs and products with the greatest value creation potential. Alongside a focus on prioritized programs, Nxera intends to implement initiatives to reduce operating expenses to support Nxera's 2030 vision of ≥JPY50 billion in net sales and an operating profit margin of ≥30%.

globenewswire.com

Nxera Pharma to Host R&D Day 2025

Tokyo, Japan and Cambridge, UK, 4 November 2025 – Nxera Pharma Co., Ltd. (“Nxera”; TSE: 4565) a technology-powered biopharmaceutical company, today announces that it will hold an R&D Day on 18 November 2025 at 17:00 JST.

globenewswire.com

Nxera Pharma Receives a Manufacturing Approval Partial Amendment Regarding the Addition of a Manufacturing Site in Asia for QUVIVIQ® 25 and 50 mg

Tokyo, Japan and Cambridge and London, UK, 31 O ctober 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that Nxera Pharma Japan Co., Ltd. (a wholly owned subsidiary of the Company) has received a manufacturing approval partial amendment with respect to QUVIVIQ® (daridorexant) 25 and 50 mg (“the Product”). Daridorexant was launched in Japan as QUVIVIQ® for the treatment of adults with chronic insomnia in December 2024, an application for approval has been submitted for regulatory review in Taiwan, and it is undergoing Phase 3 trials in South Korea.

globenewswire.com

Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2025

Tokyo, Japan and Cambridge, UK, 31 October 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the third quarter and nine months ended 30 September 2025. The full report can be found here.

globenewswire.com

Nxera's Partner Cancer Research UK Presents Data from Successfully Completed Phase 1 Clinical Trial of Cancer Immunotherapy Drug HTL0039732 at ESMO

Tokyo, Japan and Cambridge, UK, 21 October 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) announces that its partner, Cancer Research UK, presented data from the successfully completed Phase 1 part of the ongoing Phase 1/2a clinical trial ( NCT05944237 ) of Nxera's immunotherapy drug HTL0039732 (also known as NXE0039732) at the European Society for Medical Oncology Congress (ESMO) 2025 being held 17-21 October 2025 in Berlin, Germany.

globenewswire.com

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Tokyo, Japan and Cambridge and London, UK, 30 September 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reached a second important R&D milestone under its multi-target discovery collaboration with AbbVie focused on neurological diseases, resulting in a payment of US$10 million to Nxera.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance